BDKRB1 Rabbit pAb (一抗) | Bioss

bs-8675R

BDKRB1 Rabbit pAb

缓激肽B1受体抗体

B1BKR; B1R; BKB1R; BKR1; BRADYB1; BKRB1_HUMAN; BDKRB1; BK-1 receptor;

Rabbit

KLH conjugated synthetic peptide derived from Human BDKRB1: 161-260/353 <Extracellular>

IgG

Liquid

affinity purified by Protein A

Polyclonal

40 kDa

60 kDa

1mg/ml

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Kinins are important biologically active peptides that mediate cardiovascular homeostasis, inflammation and nociception. Bradykinin, the major effector peptide of the kallikrein-kinin system, is regulated by angiotensin-converting enzyme (ACE), which degrades the peptide. Bradykinin normally exerts its effects through the activation of two seven transmembrane G-protein coupled receptors, named B1 and B2. The B2 receptor is constitutively expressed and preferentially binds full length bradykinin. Deletion of the B2 receptor leads to salt-sensitive hypertension and altered nociception in mice. The B1 receptor binds to derivatives of bradykinin and kallidin, which are produced by carboxypeptidase action to generate the products des-Arg9-bradykinin and des-Arg10-kallidin, respectively. The expression of the B1 receptor is inducible by inflammatory mediators, such as bacterial lipopolysaccharide (LPS) and cytokines. The B1 and B2 receptors represent potential therapeutic targets for treatment of inflammatory disorders and cardiovascular diseases.